Searching Content indexed under Life Sciences, Biotechnology & Nanotechnology by WilmerHale ordered by Published Date Descending.
Links to Result pages
1 2  
7 Tips For Biotech Companies Seeking Capital In A Volatile Market
The article provides a recap of the 2018 market for early-stage public biotech companies...
United States
2 Jul 2019
What High Court Will Consider In Helsinn On-Sale Bar Case
The US Supreme Court may soon resolve an issue that has sparked much debate since the enactment of the Leahy-Smith America Invents Act—namely, whether under the AIA, an inventor's sale of an invention to a third party ...
United States
5 Dec 2018
Judgment Of The Court Of Justice Of The European Union Of July 25, 2018, In Case C-528/16 Confédération Paysanne And Others
On July 25, 2018, the Court of Justice (Court), sitting in a Grand Chamber, issued its judgment in Confédération paysanne and Others, by which it found that ...
European Union
7 Aug 2018
Brexit At Halfway: Pharma And Medical Devices
The object of this Alert is to highlight some practical implications of Brexit for the supply of pharmaceutical products and medical devices in the European Union (EU) and related action items...
United States
6 Apr 2018
Nations Press for International Restrictions to Govern Genetic Sequence Data
clash over access to and use of genetic sequence data (GSD) is currently brewing on several international fronts. To date, GSD has been routinely deposited in open-source databases such as GenBank of the National Center for Biotechnology Information ..
United States
19 May 2017
Finding A Way Through A Tight Deal Space
Last year's contentious U.S. presidential election is often blamed for the slowdown in dealmaking activity in the life sciences space.
United States
17 May 2017
Allergan And Editas Medicine Enter Into Strategic R&D Alliance
Editas Medicine, Inc., a leading genome editing company, and Allergan plc, a leading global pharmaceutical company, announced that Allergan's wholly-owned subsidiary—Allergan Pharmaceuticals International Limited—and Editas Medicine . . .
United States
20 Mar 2017
Park Square And Wilmerhale Release 17th Annual Technology And Life Sciences Compensation And Entrepreneurship Study
Growth rate in salaries for private company technology executives track higher than comparable life science leaders for the second year in a row.
United States
15 Feb 2017
Wilmerhale Reps Nantero In $21M Financing For Carbon Nanotube Computer Memory
Nantero Inc., the nanotechnology company developing next-generation memory using carbon nanotubes, announced the closing of more than $21 million financing round.
United States
21 Dec 2016
Regulation Of Synthetic Biology Under The Nagoya Protocol
This December, representatives from 196 nations will come to Mexico for the 13th meeting of the Convention on Biological Diversity (CBD).
United States
15 Nov 2016
Freedom To Utilize Genetic Resources? The Nagoya Protocol Two Years Later
Two years ago this month, the N agoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits from their Utilization to the Convention on Biological Diversity ("Protocol") entered into international force.
United States
2 Nov 2016
WilmerHale Advises Catabasis Pharmaceuticals In Closing Of $11.5M Offering Of Common Stock
Catabasis Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, announced the closing of an underwritten offering of 2,875,000 shares of its common stock...
United States
14 Oct 2016
The Nagoya Protocol Two Years Later
In December 2016, the Parties to the Protocol will meet in Mexico for their second biennial meeting to further implement the agreement.
14 Oct 2016
Doryx: Third Circuit Affirms Dismissal Of Product Hopping Claim
On September 28, 2016, in Mylan Pharmaceuticals Inc. v. Warner Chilcott Public Limited Co., the Third Circuit affirmed the lower court's grant of summary judgment against antitrust claims by generic manufacturer Mylan.
United States
30 Sep 2016
‘Follow-On Biologics': Ensuring Continued Innovation In The Biotechnology Industry
New protein products will likely need more market protection than what is provided to new drug products.
United States
12 Aug 2016
Trends In Inter Partes Review Of Life Sciences Patents
A statistical analysis of inter partes review proceedings before the Patent Trial and Appeal Board shows that the PTAB is not a ‘‘death squad'' for patents.
United States
11 Jul 2016
Stay Versus Stay: How Litigation Stays Pending IPRs Impact the 30-Month
Upon initiation of a patent infringement action between branded and generic pharmaceutical companies, the Hatch-Waxman Act (21 U.S.C. § 355(j)) provides for an automatic 30-month stay of
United States
30 Mar 2016
M&A: The Last Refuge For Biotechs Seeking Funding
These are tough times in the biotech and pharmaceutical industries: Funding is drying up, investors are fleeing the space, the IPO door is pretty firmly shut, valuations are dropping, activists are lurking and the headlines are anything but kind.
United States
15 Mar 2016
Inside Views: Learning From Ebola
In 1976, Yambuku village school headmaster Mabalo Lokela felt sick when he returned from a trip to northern Zaire near the Central African Republic border. He had a high fever, diarrhea, and bleeding.
United States
16 Jul 2015
Federal Circuit Patent Updates - May 2015
Federal Circuit Patent Updates - May 2015
United States
21 May 2015
Links to Result pages
1 2